Anson M. Lee

Anson M. Lee

Auto-generated profile, based on publicly available information

Anson M. Lee

Cardiothoracic Surgery, Cardiovascular Research Center, Stanford University, Palo Alto, CA (A.M.L.).

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2009 in Circulation
Verified
Journal Article
Open access
PDF file
AAAbdulhameed Aziz
Abdulhameed Aziz
ALAnson M. Lee
Anson M. Lee
MPMichael K. Pasque
Michael K. Pasque
JLJennifer S. Lawton
Jennifer S. Lawton
NMNader Moazami
Nader Moazami
MMMarc R. Moon
Marc R. Moon
Background— Recent data suggest that octogenarians’ long-term survival after complete coronary artery bypass graft revascularization is superior to incomplete revascularization. Discriminating between variable definitions of “complete” complicates interpretation of survival data. We aimed to clarify octogenarian long-term survival rates by stratifying revascularization subtypes. Methods and Results— From 1986 to 2007, 580 patients 80 to 94 years of age underwent coronary artery bypass graft. Functional complete revascularization was defined as at least 1 graft to all diseased coronary vessels with >50% stenosis. Traditional complete revascularization was defined as 1 graft to each major arterial system with at least 50% stenosis. Incomplete revascularization was defined as leaving diseased, ungrafted regions. Revascularization was functional in 279 (48%), traditional in 181 (31%), and incomplete in 120 (21%). Long-term survival was evaluated by Kaplan-Meier analysis. Of 537 operative survivors, there were 402 late deaths. Cumulative long-term survival totaled 2890 patient-years. Late survival (Kaplan-Meier) was similar between functional (mean, 6.8 years) and traditional (6.7 years) groups ( P =0.51), but diminished with incomplete (4.2 years) revascularization ( P =0.007). Survival by group at 5 years was: 59±3% functional, 57±4% traditional, and 45±5% incomplete. Survival at 8 years was: 40±3% functional, 37±4% traditional, and 26±5% incomplete. To minimize selection bias in patients with limited life expectancy, Kaplan-Meier analysis was repeated including only patients with survival >12 months. Survival was again impaired with incomplete revascularization ( P =0.04), and there was no difference between functional and traditional complete revascularization ( P =0.73). Conclusions— Bypassing all diseased arterial vessels after revascularization does not afford significant long-term survival advantage compared to a traditional approach. Incomplete revascularization, related to more extensive disease, is associated with an 18% decline in survival. These data suggest that it is important to avoid incomplete revascularization in octogenarians, but the supplementary endeavor required to perform functional complete revascularization does not improve survival.

1 July 2010 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Verified
Journal Article
Open access
ALAnson M. Lee
Anson M. Lee
KCKal Clark
Kal Clark
MBMarci S. Bailey
Marci S. Bailey
AAAbdulhameed Aziz
Abdulhameed Aziz
RSRichard B. Schuessler
Richard B. Schuessler
RDRalph J. Damiano
Ralph J. Damiano
Objective: The Cox-Maze procedure (CMP) for the surgical treatment of atrial fibrillation (AF) traditionally has required a median sternotomy and cardiopulmonary bypass. This study describes a method using ablation technologies to create the full Cox-Maze lesion set through a 5- to 6-cm right minithoracotomy. Methods: Twenty-two consecutive patients underwent a CMP through a right mini-thoracotomy and cardiopulmonary bypass. All patients were followed prospectively with electrocardiogram and 24-hour Holter monitoring at 3, 6, and 12 months. The CMP lesion set was created using bipolar radiofrequency energy and cryotherapy. Results: There was no operative mortality or major complications. Two patients required a permanent pacemaker. Five patients (23%) had early atrial tachyarrhythmias. At last follow-up (mean, 18 ± 12 months), all the patients (n = 22) were free from atrial dysrhythmias. At 3 months (n = 19), 84% of patients were off antiarrhythmic drugs. At 6 months (n = 18), 94% of patients were free from AF and off antiarrhythmic medications. At 12 months (n = 16), 81% of patients were free from AF and off antiarrhythmic drugs and three patients remained on warfarin for a mechanical mitral valve. Conclusions: A full CMP can be performed through a right mini-thoracotomy with outstanding short-term results. This less invasive procedure can be offered to patients without compromising efficacy.

1 September 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
YSYasuhiro Shudo
Yasuhiro Shudo
SGSabina Pw Guenther
Sabina Pw Guenther
BLBharathi Lingala
Bharathi Lingala
HHHao He
Hao He
WHWilliam Hiesinger
William Hiesinger
YWY. Joseph Woo
Y. Joseph Woo

29 August 2005 in The Heart Surgery Forum
Verified
Journal Article
Closed access
PDF file
SGSydney L. Gaynor
Sydney L. Gaynor
GBGregory D. Byrd
Gregory D. Byrd
MDMichael D. Diodato
Michael D. Diodato
YIYosuke Ishii
Yosuke Ishii
ALAnson M. Lee
Anson M. Lee
RJRalph J. Damiano Jr.
Ralph J. Damiano Jr.
Introduction: Microwave ablation has been used clinically for the surgical treatment of atrial fibrillation, particularly during valve procedures. However, dose- response curves have not been established for this surgical environment. The purpose of this study was to examine dosimetry curves for the Flex 4 and Flex 10 microwave devices in an acute cardioplegia-arrested porcine model. Methods: Twelve domestic pigs (40-45 kg) were acutely subjected to Flex 4 (n = 6) and Flex 10 (n = 6) ablations. On a cardioplegically arrested heart maintained at 10-15oC, six endocardial atrial and seven epicardial ventricular lesions were created in each animal. Ablations were performed for 15 s, 30 s, 45 s, 60 s, 90 s, 120 s, and 150 s (65 W, 2.45 GHz). The tissue was stained with 2,3,5-triphenyl-tetrazolium chloride and lesions were sectioned at 5 mm intervals. Lesion depth and width were determined from digital photomicrographs of each lesion (resolution .03 mm). Results: Average atrial thickness was 2.88 .4 mm (range 1.0 to 8.0 mm). 94% of ablated atrial sections created by the FLEX 4 (n = 16) and the FLEX 10 (n = 16) were transmural at 45 seconds. 100% of atrial sections were transmural at 90 seconds with the FLEX 10 (n = 14) and at 60 seconds with the Flex 4 device (n = 15). Lesion width and depth increased with duration of application. Conclusion: Both devices were capable of producing transmural lesions on the cardioplegically arrested heart at 65 W. These curves will allow surgeons to ensure transmural ablation by tailoring energy delivery to the specific atrial geometry.

26 November 2025 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
GWGabe Weininger
Gabe Weininger
JAJoy Aparicio-Valenzuela
Joy Aparicio-Valenzuela
TYTiffanie Yau
Tiffanie Yau
AVAndre Vu
Andre Vu
TPTerrence Pong
Terrence Pong
ALAnson M. Lee
Anson M. Lee

1 October 2025 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
KEKenneth Alan Ellenbogen
Kenneth Alan Ellenbogen
AKAli Khoynezhad
Ali Khoynezhad
MMMark La Meir
Mark La Meir
Carlo de AsmundisCarlo de Asmundis
Carlo de Asmundis
JKJayanthi N. Koneru
Jayanthi N. Koneru
VKVigneshwar Kasirajan
Vigneshwar Kasirajan
BACKGROUND: Despite advances in endocardial catheter ablation (ECA) for persistent atrial fibrillation (PersAF), undertreatment persists, especially in ECA nonresponders and in longstanding PersAF (LSPersAF), with disappointing ablation results. These patients need effective clinical treatment options. METHODS: The DEEP (Dual Epicardial and Endocardial Procedure) was a prospective, multicenter, single-arm, investigational device exemption trial to establish the safety and effectiveness of a combined epicardial/endocardial ablation procedure with left atrial appendage exclusion for PersAF/LSPersAF. Eligibility included age 18 to 75 years; symptomatic PersAF/LSPersAF refractory to ≥1 Class I/III antiarrhythmic drug; and ≤2 previous failed ECAs. Two-stage hybrid ablation included ECA performed at 91 to 121 days after the epicardial first stage (including left atrial appendage exclusion), followed by a 90-day blanking and 90-day antiarrhythmic drug optimization period. Primary effectiveness was defined as freedom from documented atrial fibrillation/atrial flutter/atrial tachycardia episodes >30 seconds through the 12-month follow-up, absent Class I/III antiarrhythmic drugs, except previously failed antiarrhythmic drugs at doses not exceeding those previously failed. Primary safety was defined as a composite of device/procedure-related serious adverse events within 30 days of epicardial ablation and 7 days of ECA. RESULTS: Ninety patients enrolled from February 2015 to December 2020; 83.3% (75/90) were male and mean±SD age was 63.4±7.7 years. AF classification was 83.3% (75/90) PersAF/16.7% (15/90) LSPersAF, and 47.8% (43/90) had prior ECA. The composite serious adverse events rate was 6.7% (6/90 [95% CI, 2.5%–13.9%]; P <0.001 versus safety goal), including 3 patients experiencing serious adverse events within 30 days of the epicardial procedure and 3 patients within 7 days of the endocardial procedure, all of whom were anticoagulated at the time of the event. Primary effectiveness through 12 months was 71.8% (61/85 [95% CI, 62.2%–81.3%]; P =0.0134 versus performance goal) and was 62.4% (53/85 [95% CI, 52.1%–72.7%]) through 2 years. CONCLUSIONS: A collaborative hybrid ablation approach to treating PersAF/LSPersAF is safe and effective. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02393885.